Cargando…
Urinary F(2)-Isoprostanes as a Biomarker of Reduced Risk of Type 2 Diabetes
OBJECTIVE: We have previously reported evidence of an inverse association between a urinary F(2)-isoprostane and type 2 diabetes risk in a pilot case-control study nested within the Insulin Resistance Atherosclerosis Study (IRAS). Here, we report the results from the study extended to the entire IRA...
Autores principales: | Il'yasova, Dora, Spasojevic, Ivan, Base, Karel, Zhang, Haoyue, Wang, Frances, Young, Sarah P., Millington, David S., D’Agostino, Ralph B., Wagenknecht, Lynne E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241306/ https://www.ncbi.nlm.nih.gov/pubmed/22100959 http://dx.doi.org/10.2337/dc11-1502 |
Ejemplares similares
-
Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI
por: Il’yasova, Dora, et al.
Publicado: (2012) -
Urinary F2-Isoprostanes and Metabolic Markers of Fat Oxidation
por: Il'yasova, Dora, et al.
Publicado: (2015) -
A Pilot Study of Associations Between Visceral Fat, IL-6, and Urinary F(2)-Isoprostanes in Older Adults Exposed to a Diet Intervention
por: Hoover, Sarah E, et al.
Publicado: (2021) -
Effects of 2 years of caloric restriction on oxidative status assessed by urinary F2‐isoprostanes: The CALERIE 2 randomized clinical trial
por: Il'yasova, Dora, et al.
Publicado: (2018) -
African Ancestry Gradient Is Associated with Lower Systemic F(2)-Isoprostane Levels
por: Annor, Francis, et al.
Publicado: (2017)